Latest News
Create custom blog pages using custom grids
Persica Pharmaceuticals presents new analyses of microbiology assay sensitivity and intradiscal antibiotic exposure response in chronic Low Back Pain at ASPN 2026 Annual Conference
Poster presentation builds on Phase 1b PP353 data published in The
Read moreAbstract award at American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
We are pleased to announce that Dr. Joshua Hirsch has been honored with a Top
Read morePersica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer
New senior executives bring significant biopharma experience as Persica moves
Read morePersica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
ASIPP presentation follows publication of positive data from PP353 Phase 1b
Read morePositive Clinical Data for PP353 Published in The Lancet’s eClinicalMedicine
Persica Pharmaceuticals’ Positive Clinical Data for PP353 Treatment of
Read moreTalking non-opioid pain therapies with the FT
In November 2025, our CEO Steve Ruston participated in a fireside chat with FT
Read moreQ&A with Joshua Hirsch, Neurointerventionalist at Massachusetts General Hospital and Professor at Harvard Medical School
Please introduce yourself and tell us what you do I’m a
Read morePersica strengthens global IP portfolio with EU patent granted for PP353
London, UK, 11 June 2025 – Persica Pharmaceuticals Limited (Persica), a
Read morePersica Pharmaceuticals in the news 2025
During 2025, Persica has been featured in a number of publications across
Read moreQ&A with Lloyd Czaplewski, Ph.D., CSO of Persica Pharmaceuticals
Q1) Can you tell us a bit about your background? How did you become involved in
Read morePersica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a
Read moreQ&A with Steve Ruston, Chief Executive Officer
Q&A with Steve Ruston, Chief Executive Officer What is Persica’s mission?
Read more